Offering SPR-BLI Services - Proteins provided for free!
Get your basement membrane extract free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Projektelement | Hinweise | Forschungsphase | Anforderungen an eine Zusammenarbeit |
BMA202201 | Advanced solid tumors | Phase 1 | License-out or co-development |
5e5 of 293T-CD40L cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of Alexa Fluor 647-Labeled Human CD40 Protein, Fc Tag (Cat. No. CD0-HA256) and negative control protein respectively. Alexa 647 signal was used to evaluate the binding activity (QC tested).
Expression analysis of human CD40 on Human CD40 (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human CD40 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human CD40 antibody.
Loaded Human CD40 Protein, Mouse IgG2a Fc Tag (Cat. No. CD0-H525a) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.911 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Rhesus macaque CD40, Fc Tag (Cat. No. CD0-C5259) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.829 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
LVGN-7409 | LVGN7409; LVGN-7409 | Phase 1 Clinical | Lyvgen Biopharma(HK)Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Papillomavirus Infections; Uveal melanoma; Sarcoma; Neoplasm Metastasis; Carcinoma, Hepatocellular | Details |
CD40.HIVRI.Env Vaccine | Phase 1 Clinical | Anrs | HIV Infections | Details | |
SHR-1704 | SHR-1704 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms | Details |
BI-655064 | BI-655064 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis | Details |
OPT-101 | Phase 1 Clinical | Op-T LLC | Diabetes Mellitus, Type 1 | Details | |
ILB-2101 | ILB-2101 | Phase 1 Clinical | Innolake Biopharm (Hangzhou) Co Ltd | Neoplasms | Details |
2141-V11 | 2141-V11 | Phase 1 Clinical | Darell Bigner | Ganglioglioma; Urinary Bladder Neoplasms; Glioma | Details |
MIL-97 | MIL-97 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours | Details |
BSI-038 | BSI-038 | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours | Details |
Bleselumab | 4D-11; ASKP-1240 | Phase 2 Clinical | Kyowa Hakko Kogyo Co Ltd | Rejection of renal transplantation; Rejection of organ transplantation; Psoriasis; Glomerulosclerosis, Focal Segmental | Details |
YH-008 | YH-008 | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
MP-0317 | MP-0317 | Phase 1 Clinical | Molecular Partners Ag | Solid tumours; Neoplasms | Details |
Inezetamab | AMG-994 | Phase 1 Clinical | Amgen Inc | Solid tumours; Neoplasms | Details |
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Cifurtilimab | SEA-CD40 | Phase 2 Clinical | Seattle Genetics Inc | Lymphoma, B-Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Lymphoma, Follicular; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Ravagalimab | ABBV-323; PR-1629977 | Phase 2 Clinical | Abbvie Inc | Sjogren's Syndrome; Colitis, Ulcerative | Details |
Giloralimab | ABBV-927 | Phase 2 Clinical | Abbvie Inc | Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Iscalimab | CFZ-533; NVP-CFZ533; OM11-62-MF | Phase 2 Clinical | Novartis Pharma Ag | Diabetes Mellitus, Type 1; Rejection of renal transplantation; Myasthenia Gravis; Rejection of liver transplantation; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic; Graves Disease; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa | Details |
Anti-CD40 ChiLob7/4 (BioNTech) | Phase 2 Clinical | Biontech Se | Head and Neck Neoplasms; Pancreatic Neoplasms | Details | |
Mitazalimab | ADC-1013; JNJ-7107; JNJ-64457107 | Phase 2 Clinical | Alligator Bioscience Ab | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Pancreatic Ductal | Details |
KPL-404 | KPL-404 | Phase 2 Clinical | Kiniksa Pharmaceuticals Ltd | Arthritis, Rheumatoid | Details |
NJA-730 | NJA-730; NJA-730a; NJA-730b | Phase 1 Clinical | Napajen Pharma | Autoimmune Diseases | Details |
Tecaginlimab | BNT-312; GEN-1042 | Phase 2 Clinical | Genmab A/S | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
TQB-2916 | TQB2916; TQB-2916 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
RO-7300490 | RO-7300490; RG-6189 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
Sotigalimab | APX-005M; EPI-0050; APX-005 | Phase 2 Clinical | Epitomics Inc | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lung Neoplasms; Glioma; Astrocytoma; Sarcoma; Microsatellite Instability; Central Nervous System Neoplasms; Ependymoma; Neoplasms; Carcinoma, Transitional Cell; Glioblastoma; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Medulloblastoma | Details |
HPV CD40 HVac | HPV CD40 HVac | Phase 2 Clinical | LinKinVax | Oropharyngeal Neoplasms | Details |
SL-172154 | SL-172154 | Phase 1 Clinical | Shattuck Labs Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Myelodysplastic Syndromes; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms | Details |
CDX-1140 | CDX-1140 | Phase 2 Clinical | Celldex Therapeutics | Uveal melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Waldenstrom Macroglobulinemia; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Lymphoma, Follicular; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, Mantle-Cell; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Pancreatic Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Lymphoma, B-Cell, Marginal Zone; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms; Lymphoma, B-Cell | Details |
IMB-071703 | IMB071703; IMB-071703 | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
YH-003 | YH-003; YH003 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma | Details |
CD40L-GVAX | GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF | Phase 2 Clinical | University Of South Florida | Leukemia; Adenocarcinoma of Lung; Myelodysplastic Syndromes; Lung Neoplasms; Melanoma; Adenocarcinoma | Details |
NG-350A | NG-350A | Phase 1 Clinical | Akamis Bio Ltd | Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.